On January 4, Genting Xinyao released its strategic plan for the next two years and beyond, the company will further transform into a comprehensive biopharmaceutical company, realize the whole industry chain layout, including strong independent R&D and licensing capabilities, clinical development capabilities, and large-scale production and commercialization capabilities
.
The company's nephropathy and mRNA platform portfolio will be a key development area for Genting New Yao, with a variety of promising early and late stage product candidates in both areas
.
In addition, the relevant person in charge also said that in the next stage of the company's development, it will be committed to building commercialization capabilities, with Nefecon as the pioneer, and successfully launching a number of innovative drugs and vaccines
with huge unmet medical needs in the next five years.
It is reported that Nefecon is the main product in Genting Xinyao nephrology product portfolio and is expected to be approved for marketing
in China in the second half of 2023.
In fact, in recent years, with the intensification of changes in the pharmaceutical industry and the increasingly fierce market competition, many pharmaceutical companies are actively transforming and upgrading in response to the changing industry development trends, and have also made some new strategic plans
.
Among them, it is worth mentioning that due to the current vigorous promotion of the development of the pharmaceutical innovation industry in China, R&D innovation has gradually become the key to pharmaceutical companies becoming stronger and bigger, and more and more pharmaceutical companies obviously have more plans
in innovative R&D.
For example, Taiji Group has long said that the company lists scientific and technological innovation as the first of its corporate development strategy, as an important means to promote the high-quality development of enterprises, and reshapes the scientific research system by actively exploring and improving the scientific and technological innovation mechanism, and strengthens the supporting role
of scientific and technological innovation in operation 。 Clarify the direction of R&D, focus on the "6+1" key areas and anchor 12 product tracks, with traditional Chinese medicine as the core, supplemented by chemical drugs, biological drugs, and health products; Strengthen the R&D team, establish a dual-channel system for the career development of scientific research personnel in technology and management, and implement an incentive mechanism for salary and treatment; Build a research and development platform, accelerate the construction of Taiji science and technology innovation center, strengthen scientific research cooperation with domestic and foreign countries, establish an industry-university-research integration platform, and improve scientific research infrastructure; Increase R&D investment, incorporate R&D investment intensity into the performance assessment of subsidiaries, and strive to exceed 5%
of the company's industrial sales revenue by the end of the "14th Five-Year Plan".
In addition, Northeast Pharmaceutical also plans to introduce 2 to 3 clinical-stage chemical innovative drugs and 1-2 clinical-stage bioinnovative drugs from outside in the next 5 years, and obtain 3 to 7 generic drug production approvals every year, steadily increasing the proportion of
new product revenue.
Of course, in addition to pharmaceutical companies, some domestic pharmaceutical machinery companies have already revealed their future development plans
.
For example, in December 2021, Chutian Technology mentioned the key measures and growth plans
for the next stage.
Specifically, in the next stage, it will make efforts from two aspects: products and markets, among which products include increasing efforts to maintain existing advantages, focusing on the development of biomedical equipment, and forming an innovative drug equipment development team to develop intelligent new products
.
There are three directions in the market, including vigorously promoting the replacement of high-end medical equipment; Strong overseas expansion
.
Establish sales and service companies in key markets, and localize; export substitution, etc
.
In its earlier disclosure of the research content, it was also revealed that in the next 3-5 years, the export business will maintain an annual increase of 10%-20%, and by about 2025, the export business income of Chutian headquarters will account for 40%-50% of the total revenue, accounting for half of the total revenue
.
In addition, Tailin Biotech also publicly stated the planning of the company's various business segments and the direction
of future key development.
Among them, it is clearly stated that the company will always practice the mission of "serving human health and benefiting the world", focusing on the main theme of life and health industry, deeply cultivating the R & D and production of high-end equipment and consumables in the fields of pharmaceutical engineering, cell engineering, medical engineering, biological environmental protection engineering, etc
.
, providing system service solutions, carrying out domestic substitution of high-end instruments and equipment and participating in international high-end competition.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
